GDC-0879

Modify Date: 2024-01-02 10:35:40

GDC-0879 Structure
GDC-0879 structure
Common Name GDC-0879
CAS Number 905281-76-7 Molecular Weight 334.372
Density 1.4±0.1 g/cm3 Boiling Point 562.6±50.0 °C at 760 mmHg
Molecular Formula C19H18N4O2 Melting Point N/A
MSDS N/A Flash Point 294.0±30.1 °C

 Use of GDC-0879


GDC-0879 is a potent and selective B-Raf inhibitor with an IC50 of 0.13 nM.

 Names

Name gdc-0879
Synonym More Synonyms

 GDC-0879 Biological Activity

Description GDC-0879 is a potent and selective B-Raf inhibitor with an IC50 of 0.13 nM.
Related Catalog
Target

B-Raf:0.13 nM (IC50)

In Vitro GDC-0879 also inhibits pERK with an IC50 of 63 nM[1]. GDC-0879 represents a novel potent and selective B-Raf inhibitor that is being evaluated as a potential antitumor agent. GDC-0879 exhibits potent inhibition of Raf/MEK/ERK signaling pathway in V600E B-Raf mutant cell lines with low cellular pMEK1 inhibition IC50 estimates of 59 and 29 nM in A375 melanoma and Colo205 colorectal carcinoma cells, respectively[2].
In Vivo The pharmacokinetic parameters of GDC-0879 after oral administration of 15, 25, 50, 100, and 200 mg/kg in MCT in mice are estimated as follows: ka=8.20 h-1, ke=0.59 h-1, and apparent volume of distribution=6.19 L/kg[2].
Cell Assay GDC-0879 in vitro IC50 estimates for pMEK inhibition are determined using A375 and Colo205 cells. In brief, A375 or Colo205 cells are incubated with a range of GDC-0879 concentrations (from 0.5 nM to 6.75 μM) for 25 min. Cells are lysed, and the lysates are subjected to centrifugation at 16,100g for 30 min, and the level of total protein is determined. Enzyme-linked immunosorbent assay kits are used to determine pMEK1 and total MEK1 protein levels in a 96-well format. Samples are analyzed in duplicate at 20 μg of protein per well. The optical densities obtained at 450 nm are converted to units per milliliter (for pMEK1) or nanograms per milliliter (for total MEK1) using a standard curve determined with recombinant pMEK1 or MEK1. The pMEK1/total MEK1 ratios are then calculated as units per nanogram. The IC50 estimates for pMEK1 inhibition are estimated by nonlinear regression using GraphPad Prism version 4.02[2].
Animal Admin Mice[2] Female athymic nu/nu mice (weighing 25-28 g) are administered oral doses of 15, 25, 50, 100, and 200 mg/kg GDC-0879. Blood samples (~1 mL) are collected at 0.5, 1, 2, 4, 8, and 24 h after dose via cardiac puncture (terminal collection) into tubes containing K2EDTA anticoagulant. Immediately upon collection, the blood is mixed with K2EDTA and stored on ice. Within 30 min, blood samples are centrifuged at approximately 1000 to 1500g for 5 min at 4°C, and plasma is harvested. The plasma samples are stored at -80°C until analysis[2].
References

[1]. Hansen JD, et al. Potent and selective pyrazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4692-5.

[2]. Wong H, et al. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J Pharmacol Exp Ther. 2009 Apr;329(1):360-7.

 Chemical & Physical Properties

Density 1.4±0.1 g/cm3
Boiling Point 562.6±50.0 °C at 760 mmHg
Molecular Formula C19H18N4O2
Molecular Weight 334.372
Flash Point 294.0±30.1 °C
Exact Mass 334.142975
PSA 83.53000
LogP 1.12
Vapour Pressure 0.0±1.6 mmHg at 25°C
Index of Refraction 1.705
Storage condition -20℃

 Synonyms

GDC-0879
2-{4-[(1E)-1-(Hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(4-pyridinyl)-1H-pyrazol-1-yl}ethanol
1H-Inden-1-one, 2,3-dihydro-5-[1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl]-, oxime, (1E)-
2,3-Dihydro-5-[1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl]-1H-inden-1-one oxime
Top Suppliers:I want be here


Get all suppliers and price by the below link:

GDC-0879 suppliers


Price: $132/10mM*1mLinDMSO

Reference only. check more GDC-0879 price